用於癌症以及傳染病的免疫療法與疫苗

用於癌症以及傳染病的免疫療法與疫苗 是由出版商Insight Pharma Reports在2008年10月所出版的。 這份英文市場調查報告書包含390 pages 價格從美金3195起跳。

簡介

目錄

Abstract

The field of therapeutic vaccines and immunotherapies is rapidly emerging as a promising area. Use of passive immunotherapy (i.e., antibody) products, for prevention of infection or for treatment of many diseases, including cancer, is widespread. In addition, some nonspecific immunomodulators on the market are used to treat certain cancers. However, there is considerable interest in the development of novel, active specific immunotherapies and therapeutic vaccines for cancer. No active specific immunotherapy products have yet reached the market in the United States, but we may be getting close. Progress is also being made in the development of therapeutic vaccines and immunotherapies for treatment of chronic infectious diseases.

Immunotherapies and Vaccines for Cancer and Infectious Diseases reviews current pharmacological options for 12 major cancers being targeted by companies developing cancer immunotherapies or vaccines. While a large number of drugs are available for these particular cancers, poor survival rates demonstrate there is a clear need for more effective treatments. We then include a discussion of currently available immunotherapies for chronic infections, and infectious disease vaccines that are on the market.

We consider strategies companies are using to develop cancer immunotherapies and vaccines, as well as different types of infectious disease vaccines, and highlight the R&D challenges for these sectors. A large number of smaller biopharmaceutical companies, and a more limited number of major pharmaceutical companies, are developing a wide range of different approaches to stimulate the immune system.

The many different product candidates that are in development for the 12 cancers targeted in this report are reviewed. In addition, we briefly touch upon the numerous vaccines and immunotherapies that are in development for other cancers.

In our section on infectious disease, we discuss novel prophylactic vaccines that are in development for prevention of a wide range of different diseases. We then focus on therapeutic vaccines and immunotherapies being developed for treatment of chronic infections.

Immunotherapies and Vaccines for Cancer and Infectious Diseases examines a number of business considerations and trends in the fields of infectious disease and cancer immunotherapies and vaccines. Interviews with nine experts in this area are provided, giving their perspectives on the progress being made, and the challenges and hurdles faced by researchers and companies working in this emerging field.

Table of Contents

• INTRODUCTION
• 1.1. The Immune System
• 1.2. Scope of This Report

• MAJOR CANCERS AND INFECTIOUS DISEASES TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO ENHANCE THE IMMUNE SYSTEM
• 2.1. Major Cancers Targeted by Immunotherapies and Vaccines
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Leukemia
  • Lung Cancer
    • Non - Small-Cell Lung Cancer
    • Small-Cell Lung Cancer
  • Lymphoma (Non - Hodgkin' s Lymphoma)
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cancer
• 2.2. Major Infectious Diseases Targeted by Emerging Immunotherapies and Vaccines
  • Anthrax
  • Campylobacter
  • Cytomegalovirus
  • Dengue
  • Diphtheria
  • Encephalitis
  • Haemophilus influenzae Type b
  • Hepatitis B Virus
  • Hepatitis C Virus
  • Herpes Simplex Virus
  • Human Immunodeficiency Virus
  • Human Papillomavirus
  • Influenza
  • Malaria
  • Meningococcal Disease; Neisseria meningitidis
  • Pertussis
  • Pneumococcal Disease; Streptococcus pneumoniae
  • Polio (Poliomyelitis)
  • Respiratory Syncytial Virus
  • Tetanus
  • Tuberculosis
  • West Nile Virus

• CURRENT PHARMACOLOGICAL OPTIONS FOR TREATMENT AND PREVENTION OF CANCER, AND IMMUNOTHERAPY/VACCINE OPTIONS FOR TREATMENT AND PREVENTION OF INFECTIOUS DISEASES
• 3.1. Current Pharmacological Options for Treatment and Prevention of Cancer
  • Brain Cancer
  • Breast Cancer
    • Chemotherapy
    • Hormone Therapy
    • Targeted Therapy: HER2-Positive Cancers
    • Targeted Therapy: VEGF and Angiogenesis
  • Cervical Cancer
  • Colorectal Cancer
    • Chemotherapy
    • Targeted Therapy: Monoclonal Antibodies
  • Leukemia
    • Pharmacological Therapies (Chemotherapy and Others)
    • Bone Marrow Transplants and Peripheral Stem Cell Transplants
  • Lung Cancer
    • Chemotherapy (Non - Small-Cell Lung Cancer)
    • Targeted Therapy: Kinase Inhibitors (Non - Small-Cell Lung Cancer)
    • Targeted Therapy: Monoclonal Antibodies (Non - Small-Cell Lung Cancer)
    • Photodynamic Therapy (Non - Small-Cell Lung Cancer)
    • Chemotherapy (Small-Cell Lung Cancer)
  • Lymphoma (Non - Hodgkin' s Lymphoma)
    • Chemotherapy
    • Monoclonal Antibodies
    • Other Immune-Based Therapies
    • Other Targeted Therapies: Histone Deacetylase Inhibitor
  • Melanoma
    • Interferon
    • Interleukin-2
    • Chemotherapy
    • Ovarian Cancer
  • Pancreatic Cancer
    • Chemotherapy
    • Targeted Therapy: Inhibition of EGFR Tyrosine Kinase
  • Prostate Cancer
    • Luteinizing Hormone - Releasing Hormone Agonists
    • Antiandrogens
    • Chemotherapy
  • Renal Cancer
    • Interferon
    • Interleukin-2
  • Targeted Therapy: Kinase Inhibitors
• 3.2. Current Infectious Disease Immunotherapies and Vaccines
  • Passive Immunotherapy
  • Immunotherapy for Treatment of Chronic Infections
  • Infectious Disease Vaccines
• 3.3. Medical and Market Needs; R&D Challenges
  • Cancer Immunotherapies and Vaccines
  • Infectious Disease Immunotherapies and Vaccines

• EXAMPLES OF CURRENT AND EMERGING APPROACHES TO ENHANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
• 4.1. New Approaches for Cancer Immunotherapy and Vaccines
  • Nonspecific Active Immunotherapy (Immune-Modulating Agents)
  • Antigen Immunotherapies/Vaccines (Allogeneic)
  • Autologous Antigen Immunotherapies/Vaccines
  • Allogeneic Whole-Tumor-Cell Immunotherapies/Vaccines
  • Autologous Whole-Tumor-Cell Immunotherapies/Vaccines
  • Dendritic Cell Immunotherapies/Vaccines
  • DNA and Viral Vector Vaccines
• 4.2. Infectious Disease Vaccines
  • Types of Vaccines
  • Adjuvants

• CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
• 5.1. Brain Cancer
  • Advantagene
  • Antisense Pharma
  • Celldex Therapeutics
  • Merck Serono
  • Northwest Biotherapeutics
• 5.2. Breast Cancer
  • Antigen Express (Subsidiary of Generex Biotechnology)
  • Apthera
  • Celldex Therapeutics
  • Introgen Therapeutics
  • Peregrine Pharmaceuticals
• 5.3. Cervical Cancer
• 5.4. Colorectal Cancer
  • Celldex Therapeutics
  • GenVec
  • immatics biotechnologies
  • Oxford BioMedica and sanofi-aventis
  • Vaccinogen
• 5.5. Leukemia
  • Argos Therapeutics
  • Cell Genesys
  • Geron
  • The Vaccine Company
• 5.6. Lung Cancer
  • Agennix
  • AVAX Technologies
  • GlaxoSmithKline
  • GlobeImmune
  • IDM Pharma
  • Introgen Therapeutics
  • Merck Serono and Oncothyreon
  • Merck Serono
  • NovaRx
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmexa
  • Transgene
  • Vaxon Biotech
• 5.7. Lymphoma (Non - Hodgkin' s Lymphoma)
  • Biovest International
  • Transgene
• 5.8. Melanoma
  • Antigenics
  • AVAX Technologies
  • BioVex
  • GenVec
  • GlaxoSmithKline
  • Medarex and Bristol-Myers Squibb
  • Merck Serono
  • Oxford BioMedica
  • Sanofi Pasteur
  • SciClone Pharmaceuticals and Sigma-Tau
  • Vical
  • ZymoGenetics
• 5.9. Ovarian Cancer
  • AVAX Technologies
  • Menarini Group
• 5.10. Pancreatic Cancer
  • Celldex Therapeutics
  • Cell Genesys
  • GenVec
  • GlobeImmune
  • Lorus Therapeutics and Zor Pharmaceuticals
  • Pharmexa
• 5.11. Prostate Cancer
  • Advantagene
  • Bavarian Nordic
  • Cell Genesys
  • Dendreon
  • Northwest Biotherapeutics
  • Onyvax
  • Oxford BioMedica and sanofi-aventis
• 5.12. Renal Cancer
  • Active Biotech
  • Agennix
  • Antigenics
  • Argos Therapeutics
  • Endocyte
  • Idera Pharmaceuticals and Merck Serono
  • immatics biotechnologies
  • LipoNova
  • Oxford BioMedica and sanofi-aventis
  • ZymoGenetics
• 5.13. Immunotherapies and Vaccines in Development for Other or Nonspecified Cancer Indications

• IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES
• 6.1. Anthrax and Other Biodefense Vaccines
• 6.2. Campylobacter and/or Enterotoxigenic Escherichia coli (Traveler' s Diarrhea)
  • Ace Biosciences
  • Intercell
• 6.3. Cytomegalovirus
  • Vical
• 6.4. Dengue
  • GlaxoSmith Kline
  • Sanofi Pasteur
• 6.5. Encephalitis
  • Novartis and Intercell
  • Sanofi Pasteur
• 6.6. Hepatitis B
  • Emergent BioSolutions
  • Merck and Dynavax
• 6.7. Hepatitis C
  • GlobeImmune
  • Hemispherx Biopharma
  • Human Genome Sciences and Novartis
  • Novartis Vaccines and Intercell
  • SciClone Pharmaceuticals
• 6.8. Herpes Simplex Virus
  • GlaxoSmithKline
• 6.9. Human Immunodeficiency Virus (HIV)
  • Argos Therapeutics
  • Bionor Immuno
  • GenVec
  • Hemispherx Biopharma
  • Sanofi Pasteur
  • Targeted Genetics
• 6.10. Human Papillomavirus (HPV)
  • GlaxoSmithKline
  • Merck
  • MGI Pharma (Subsidiary of Eisai)
  • Transgene and Roche
• 6.11. Influenza
  • Baxter Vaccines
  • CSL Biotherapies
  • GlaxoSmithKline
  • Novartis Vaccines
  • Protein Sciences Corporation
  • Sanofi Pasteur
• 6.12. Malaria
  • GlaxoSmithKline
• 6.13. Meningococcal Disease; Neisseria meningitidis
  • GlaxoSmithKline
  • Novartis
• 6.14. Pneumococcal Disease; Streptococcus pneumoniae
  • GlaxoSmithKline
  • Wyeth
• 6.15. Respiratory Syncytial Virus
• 6.16. Tuberculosis
  • Emergent BioSolutions
  • GlaxoSmithKline
• 6.17. West Nile Virus
  • Sanofi Pasteur
• 6.18. Emerging Combination Vaccines
• 6.19. Other Emerging Infectious Disease Vaccines

• SELECTED BUSINESS CONSIDERATIONS: IMMUNOTHERAPIES AND VACCINES THAT ENHANCE THE IMMUNE SYSTEM
• 7.1. Companies in the Infectious Disease and Cancer Vaccines and Immunotherapies Fields
• 7.2. Diseases Targeted for Product Development
  • Infectious Disease
  • Cancer
• 7.3. Technical Issues and Challenges for Cancer and Infectious Disease Vaccines and Immunotherapies
• 7.4. Partners (Corporate and Noncorporate) and Acquisitions
• 7.5. Human Papillomavirus - Infectious Disease Prophylactic Vaccine for Prevention of Cancer: Example of a Controversy with a New Vaccine
  • Social Issues
  • Safety Issues

• EXPERT INTERVIEWS
• Estuardo Aguilar-Cordova, MD, Founder & Chief Executive Officer, Advantagene, Inc., Waban, MA
• David Apelian, MD, PhD, MBA, Vice President, Clinical Development and Regulatory Affairs, and Chief Medical Officer, GlobeImmune, Louisville, CO
• Robert Coffin, PhD, Chief Technology Officer, Founder and Director, BioVex, Woburn, MA
• Raafat E.F. Fahim, PhD, President and Chief Executive Officer, Nabi Pharmaceuticals, Rockville, MD
• Drew Hannaman, Vice President, Research and Development, Ichor Medical Systems, San Diego, CA
• Kristen M. Hege, MD, Vice President, Clinical Research and Development, Cell Genesys, South San Francisco, CA
• Frank Malinoski, MD, PhD, Senior Vice President, Medical and Scientific Affairs, MedImmune, Gaithersburg, MD
• Cynthia W. Tuthill, PhD, Senior Vice President, Scientific Affairs, & Chief Scientific Officer, SciClone Pharmaceuticals, Foster City, CA
• Sunny Uberoi, Vice President, Corporate Communications, Antigenics, New York, NY

相關商品

癌症相關市場調查報告書

乳癌、大腸癌、血管增生分析
Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌、淋巴癌、血管增生分析
Triple Analysis: Colorectal Cancer, Lymphoma and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌、黑色素細胞癌、血管增生分析
Triple Analysis: Colorectal Cancer, Melanoma and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Insight Pharma Reports發行的製藥相關市場調查報告書

PI3k/Akt/mTOR途徑:開發平台分析

The PI3K/Akt/mTOR Pathway: A Pipeline Analysis - Overview

價格 : US $ 2495

出版日期 : 2011年11月

預防和治療性疫苗之新趨勢：概要

New Trends in Preventive and Therapeutic Vaccines - Overview

價格 : US $ 2495

出版日期 : 2011年10月

激酶標靶治療：開發產品線、挑戰及機會

Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities

價格 : US $ 3195

出版日期 : 2011年08月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!